相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Development of small-molecule tropomyosin receptor kinase (TRK) inhibitors for NTRK fusion cancers
Tingting Jiang et al.
ACTA PHARMACEUTICA SINICA B (2021)
Indolin-2-one derivatives as selective Aurora B kinase inhibitors targeting breast cancer
Eman M. E. Dokla et al.
BIOORGANIC CHEMISTRY (2021)
Dual Kinase Targeting in Leukemia
Luca Mologni et al.
CANCERS (2021)
FLT3 Inhibitors in Acute Myeloid Leukemia: Challenges and Recent Developments in Overcoming Resistance
Zhijie Wang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia
Abhishek Maiti et al.
BLOOD CANCER JOURNAL (2021)
Acute myeloid leukemia: current progress and future directions
Hagop Kantarjian et al.
BLOOD CANCER JOURNAL (2021)
Sunitinib-Induced Acute Liver Failure
Anum Aqsa et al.
CASE REPORTS IN GASTROENTEROLOGY (2021)
Tuning mTORC1 activity dictates the response of acute myeloid leukemia to LSD1 inhibition
Amal Kamal Abdel-Aziz et al.
HAEMATOLOGICA (2020)
Discovery and characterization of targetable NTRK point mutations in hematologic neoplasms
Sunil K. Joshi et al.
BLOOD (2020)
Cancer statistics, 2020
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
FLT3 mutations in acute myeloid leukemia: Therapeutic paradigm beyond inhibitor development
Hitoshi Kiyoi et al.
CANCER SCIENCE (2020)
Overcoming Resistance to FLT3 Inhibitors in the Treatment of FLT3-Mutated AML
Stephen S. Y. Lam et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Advances in the Treatment of Acute Myeloid Leukemia: New Drugs and New Challenges
Nicholas J. Short et al.
CANCER DISCOVERY (2020)
Recent advances in FLT3 inhibitors for acute myeloid leukemia
Lexian Tong et al.
FUTURE MEDICINAL CHEMISTRY (2020)
Profile of Quizartinib for the Treatment of Adult Patients with Relapsed/Refractory FLT3-ITD-Positive Acute Myeloid Leukemia: Evidence to Date
Luke Fletcher et al.
CANCER MANAGEMENT AND RESEARCH (2020)
Quizartinib, a selective FLT3 inhibitor, maintains antileukemic activity in preclinical models of RAS-mediated midostaurin-resistant acute myeloid leukemia cells
Tomoya Aikawa et al.
Oncotarget (2020)
In Search of Outliers. Mining for Protein Kinase Inhibitors Based on Their Anti-Proliferative NCI-60 Cell Lines Profile
George Nicolae Daniel Ion et al.
MOLECULES (2020)
Advances in targeted therapy for acute myeloid leukemia
Jifeng Yu et al.
BIOMARKER RESEARCH (2020)
A phase 1/2 study of the oral FLT3 inhibitor pexidartinib in relapsed/refractory FLT3-ITD-mutant acute myeloid leukemia
Catherine C. Smith et al.
BLOOD ADVANCES (2020)
Small-Molecule Fms-like Tyrosine Kinase 3 Inhibitors: An Attractive and Efficient Method for the Treatment of Acute Myeloid Leukemia
Yue Zhong et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML
Musa Yilmaz et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
Molecular Mechanisms of Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia: Ongoing Challenges and Future Treatments
Sebastian Scholl et al.
CELLS (2020)
FLT3 Mutations in Acute Myeloid Leukemia: Key Concepts and Emerging Controversies
Vanessa E. Kennedy et al.
FRONTIERS IN ONCOLOGY (2020)
Inhibition of Tropomyosin Receptor Kinase A Signaling Negatively Regulates Megakaryopoiesis and induces Thrombopoiesis
Ayse Kizilyer et al.
SCIENTIFIC REPORTS (2019)
Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial
Jorge E. Cortes et al.
LANCET ONCOLOGY (2019)
Dual FLT3 inhibitors: Against the drug resistance of acute myeloid leukemia in recent decade
Ting Yuan et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2019)
Recent drug approvals for acute myeloid leukemia
Catherine Lai et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Comparing apples with oranges: Studying LSD1 inhibitors in cellular assays
Amal Kamal Abdel-Aziz et al.
PHARMACOLOGICAL RESEARCH (2019)
Larotrectinib, a highly selective tropomyosin receptor kinase (TRK) inhibitor for the treatment of TRK fusion cancer
Noah Federman et al.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2019)
FLT3-ITD Enhances Proliferation and Survival of AML Cells through Activation of RSK1 to Upregulate the mTORC1/eIF4F Pathway Cooperatively with PIM or PI3K and to Inhibit Bad and Bim
Ayako Nogami et al.
BLOOD (2019)
1,2,4-Oxadiazole derivatives targeting EGFR and c-Met degradation in TKI resistant NSCLC
Eman M. E. Dokla et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2019)
Two Receptors, Two Isoforms, Two Cancers: Comprehensive Analysis of KIT and TrkA Expression in Neuroblastoma and Acute Myeloid Leukemia
Timofey D. Lebedev et al.
FRONTIERS IN ONCOLOGY (2019)
Targeting FLT3 mutations in AML: review of current knowledge and evidence
Naval Daver et al.
LEUKEMIA (2019)
Emerging treatment paradigms with FLT3 inhibitors in acute myeloid leukemia
Nicholas J. Short et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2019)
Antitumor Activity of Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor, in ETV6-NTRK3-Positive Acute Myeloid Leukemia
Kristen M. Smith et al.
MOLECULAR CANCER THERAPEUTICS (2018)
Dual FLT3/TOPK inhibitor with activity against FLT3-ITD secondary mutations potently inhibits acute myeloid leukemia cell lines
Neetu Dayal et al.
FUTURE MEDICINAL CHEMISTRY (2018)
Characterization of TRKA signaling in acute myeloid leukemia
Shelley M. Herbrich et al.
Oncotarget (2018)
Comparison of the Kinase Profile of Midostaurin (Rydapt) with That of Its Predominant Metabolites and the Potential Relevance of Some Newly Identified Targets to Leukemia Therapy
Paul W. Manley et al.
BIOCHEMISTRY (2018)
Oncogenic TRK fusions are amenable to inhibition in hematologic malignancies
Justin Taylor et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Synthesis and in vitro evaluation of diverse heterocyclic diphenolic compounds as inhibitors of DYRK1A
Qingqing Zhou et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2018)
Resistance to FLT3 inhibitors in acute myeloid leukemia: Molecular mechanisms and resensitizing strategies
Jianbiao Zhou et al.
WORLD JOURNAL OF CLINICAL ONCOLOGY (2018)
A novel irreversible FLT3 inhibitor, FF-10101, shows excellent efficacy against AML cells with FLT3 mutations
Takeshi Yamaura et al.
BLOOD (2018)
MZH29 is a novel potent inhibitor that overcomes drug resistance FLT3 mutations in acute myeloid leukemia
B. Xu et al.
LEUKEMIA (2017)
FLT3 and FLT3-ITD phosphorylate and inactivate the cyclin-dependent kinase inhibitor p27Kip1 in acute myeloid leukemia
Ines Peschel et al.
HAEMATOLOGICA (2017)
Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia
Masamichi Mori et al.
INVESTIGATIONAL NEW DRUGS (2017)
FLT3 inhibitors: clinical potential in acute myeloid leukemia
Marie-Anne Hospital et al.
ONCOTARGETS AND THERAPY (2017)
FLT3 and FLT3-ITD phosphorylate and inactivate the cyclin-dependent kinase inhibitor p27Kip1 in acute myeloid leukemia
Ines Peschel et al.
HAEMATOLOGICA (2017)
From Resistance to Sensitivity: Insights and Implications of Biphasic Modulation of Autophagy by Sunitinib
Amal Kamal Abdel-Aziz et al.
FRONTIERS IN PHARMACOLOGY (2017)
An update of current treatments for adult acute myeloid leukemia
Herve Dombret et al.
BLOOD (2016)
FLT3 Inhibitors for Treating Acute Myeloid Leukemia
Mona Hassanein et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2016)
Genomic Classification and Prognosis in Acute Myeloid Leukemia
Elli Papaemmanuil et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Acute myeloid leukemia: a comprehensive review and 2016 update
I. De Kouchkovsky et al.
BLOOD CANCER JOURNAL (2016)
Cell-Line Selectivity Improves the Predictive Power of Pharmacogenomic Analyses and Helps Identify NADPH as Biomarker for Ferroptosis Sensitivity
Kenichi Shimada et al.
CELL CHEMICAL BIOLOGY (2016)
Discovery of novel N-(5-(tert-butyl)isoxazol-3-yl)-N′-phenylurea analogs as potent FLT3 inhibitors and evaluation of their activity against acute myeloid leukemia in vitro and in vivo
Ying Xu et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2015)
Entrectinib: a potent new TRK, ROS1, and ALK inhibitor
Christian Rolfo et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2015)
Sorafenib: the gold standard therapy in advanced hepatocellular carcinoma and beyond
Gennaro Gadaleta-Caldarola et al.
FUTURE ONCOLOGY (2015)
FLT3 D835 mutations confer differential resistance to type II FLT3 inhibitors
C. C. Smith et al.
LEUKEMIA (2015)
Modulation of Imatinib Cytotoxicity by Selenite in HCT116 Colorectal Cancer Cells
Amal Kamal Abdel-Aziz et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2015)
Inhibition of c-Kit by tyrosine kinase inhibitors
Allison Galanis et al.
HAEMATOLOGICA (2015)
Crystal Structure of the FLT3 Kinase Domain Bound to the Inhibitor Quizartinib (AC220)
Julie A. Zorn et al.
PLOS ONE (2015)
Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants
Allison Galanis et al.
BLOOD (2014)
Chloroquine synergizes sunitinib cytotoxicity via modulating autophagic, apoptotic and angiogenic machineries
Amal Kamal Abdel-Aziz et al.
CHEMICO-BIOLOGICAL INTERACTIONS (2014)
The TPM3-NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition
Elena Ardini et al.
MOLECULAR ONCOLOGY (2014)
Crenolanib is a selective type I pan-FLT3 inhibitor
Catherine Choy Smith et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Overcoming Myelosuppression Due to Synthetic Lethal Toxicity in FLT3-Targeted Acute Myeloid Leukemia Therapy
Alexander A. Warkentin et al.
ELIFE (2014)
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
Timothy J. Ley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
CBL mutation-related patterns of phosphorylation and sensitivity to tyrosine kinase inhibitors
H. Makishima et al.
LEUKEMIA (2012)
An overview on the role of FLT3-tyrosine kinase receptor in acute myeloid leukemia: biology and treatment
Tiziana Grafone et al.
ONCOLOGY REVIEWS (2012)
Conformational Control Inhibition of the BCR-ABL1 Tyrosine Kinase, Including the Gatekeeper T315I Mutant, by the Switch-Control Inhibitor DCC-2036
Wayne W. Chan et al.
CANCER CELL (2011)
Pacritinib (SB1518), a JAK2/FLT3 inhibitor for the treatment of acute myeloid leukemia
S. Hart et al.
BLOOD CANCER JOURNAL (2011)
AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)
Patrick P. Zarrinkar et al.
BLOOD (2009)
AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance
Thomas O'Hare et al.
CANCER CELL (2009)
Comparison of antitumor effects of multitargeted tyrosine kinase inhibitors in acute myelogenous leukemia
Shuiying Hu et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Antitumor activity of sorafenib in FLT3-driven leukemic cells
D. Auclair et al.
LEUKEMIA (2007)
Design and synthesis of 1,5-diarylbenzimidazoles as inhibitors of the VEGF-receptor KDR
MT Bilodeau et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2003)
SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo
AM O'Farrell et al.
BLOOD (2003)
Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412
E Weisberg et al.
CANCER CELL (2002)
A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo
M Levis et al.
BLOOD (2002)
CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML)
LM Kelly et al.
CANCER CELL (2002)
Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies
Y Yamamoto et al.
BLOOD (2001)
分享论文
